Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has been assigned a $200.00 price objective by Oppenheimer Holdings, Inc. in a report released on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 81.82% from the company’s previous close.

A number of other equities research analysts also recently commented on ICPT. Wedbush reiterated an “outperform” rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, September 16th. Credit Suisse Group reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. Robert W. Baird reiterated an “outperform” rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. Wells Fargo & Company reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 28th. Finally, Leerink Swann reiterated a “positive” rating and issued a $159.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, October 14th. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $181.48.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 5.39% during midday trading on Wednesday, hitting $115.93. The stock had a trading volume of 331,987 shares. The firm’s market cap is $2.88 billion. Intercept Pharmaceuticals has a 52 week low of $89.76 and a 52 week high of $177.93. The stock has a 50-day moving average of $107.02 and a 200-day moving average of $137.97.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) EPS for the quarter, beating analysts’ consensus estimates of ($3.82) by $0.23. The business earned $4.70 million during the quarter, compared to the consensus estimate of $4.77 million. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The firm’s revenue was up 1051.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.10) earnings per share. Analysts forecast that Intercept Pharmaceuticals will post ($15.64) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this piece of content can be read at http://www.dailypolitical.com/2017/01/13/intercept-pharmaceuticals-inc-icpt-pt-set-at-200-00-by-oppenheimer-holdings-inc.html.

In related news, insider Rachel Mcminn sold 816 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $103.92, for a total transaction of $84,798.72. Following the completion of the transaction, the insider now directly owns 12,916 shares of the company’s stock, valued at $1,342,230.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lisa Bright sold 249 shares of the stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $113.60, for a total value of $28,286.40. Following the transaction, the insider now directly owns 18,209 shares of the company’s stock, valued at $2,068,542.40. The disclosure for this sale can be found here. Insiders own 9.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of ICPT. Principal Financial Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 2.4% in the second quarter. Principal Financial Group Inc. now owns 14,033 shares of the biopharmaceutical company’s stock valued at $2,002,000 after buying an additional 328 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $4,389,000. Teacher Retirement System of Texas boosted its position in shares of Intercept Pharmaceuticals by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 2,366 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 287 shares during the period. Schroder Investment Management Group bought a new position in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $1,508,000. Finally, Ameriprise Financial Inc. boosted its position in shares of Intercept Pharmaceuticals by 2.5% in the second quarter. Ameriprise Financial Inc. now owns 3,006,293 shares of the biopharmaceutical company’s stock valued at $428,935,000 after buying an additional 74,253 shares during the period. 82.40% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.